Media | October 1, 2024
Aventine Feature: 5 Ways to Think About Radioligands
Get the Resource
Read the FeatureAventine is a non-profit research institute that sheds light on how rapid technological advancements and disruptive change will affect the ways we live, work, and experience life in the decades to come. In a recent feature, they highlight advancements in radioligand development and the potential for these targeted treatments to transform cancer treatment.
In their “5 Ways to Think About Radioligands” series, Aventine spoke with five experts about how they view the current state of radioligand development and future applications of radioligand therapy in terms of cancer care. Sapient’s Dr. Jonathan Usuka was one of the experts tapped, and as he shares:
“Radioisotopes added to therapeutics — it just greatly increases the potency of the drug, and that’s exactly what we want for serious conditions. The danger of the toxicity is really going to be most acute in the nearby healthy tissue, especially those healthy adjacent cells. So really understanding what is going on in the immediate vicinity of the tumor, that’s going to be even more important. The good news is that we’ve had lots of technical advances recently in studying the tumor microenvironment. I would see these new therapies available to clinics to prescribe within two to three [years] and really transforming treatment over the next five years.”
See what the other experts had to say about this promising new modality to increase efficacy while significantly reducing many of the side effects of traditional radiation therapy.
